Tag: biopharmaceutical cmo and cro market outlook

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Biopharmaceutical CMO And CRO Market Over The Forecast Period?

The biopharmaceutical third-party logistics market size has experienced robust expansion in recent years. This market is projected to expand from $150.5 billion in 2025 to $161.71 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.4%. Historical growth within this sector can be attributed to several factors, including increased production of biologics and vaccines, an uptick in pharmaceutical companies outsourcing their logistics services, the broadening of global biopharmaceutical supply chains, more stringent regulatory demands for transporting drugs, and the limited internal logistics capabilities of biopharma enterprises.

The biopharmaceutical third-party logistics market size is poised for substantial growth in the coming years. It is projected to reach $221.15 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. The expansion during this forecast period stems from factors such as increasing demand for personalized medicines, the broadening distribution of cell and gene therapy, rising investments in smart logistics platforms, a growing emphasis on end-to-end supply chain visibility, and an increase in cross-border biopharmaceutical trade. Noteworthy trends for the forecast period include the increasing adoption of advanced cold chain logistics solutions, a rising need for temperature-monitored transportation services, wider use of real-time shipment tracking platforms, the expansion of specialized biopharma warehousing infrastructure, and an enhanced focus on regulatory-compliant logistics operations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19337&type=smp

What Market Drivers Are Helping Shape The Biopharmaceutical CMO And CRO Market Expansion?

The increasing inclination towards outsourcing logistics is anticipated to fuel expansion within the biopharmaceutical third-party logistics market. This process entails employing an external entity to manage either a full range or specific segments of a firm’s logistics operations. Within biopharmaceutical third-party logistics, outsourcing logistics is utilized for entrusting cryogenic supply chain management to specialized logistics partners. As an illustration, figures from February 2024 reported by the Bureau of Transportation Statistics, a US-based division of the Department of Transportation (DOT), showed that for-hire freight shipments experienced a 1.8% increase in December 2023 relative to December 2022. Concurrently, the Freight Transportation Services Index climbed from 136.6 in December 2022 to 139.1 in December 2023. Consequently, the growing adoption of outsourced logistics is projected to accelerate the expansion of the biopharmaceutical third-party logistics market.

What Are The Major Segment Categories Within The Biopharmaceutical CMO And CRO Market?

The biopharmaceutical cmo and cro market covered in this report is segmented –

1) By Product: Biologics, Biosimilars

2) By Service Type: Contract Manufacturing, Contract Research

3) By Source: Mammalian, Non-Mammalian

Subsegments:

1) By Biologics: Monoclonal Antibodies (mAbs), Vaccines, Recombinant Proteins, Cell and Gene Therapies, Antibody-Drug Conjugates (ADCs), Therapeutic Enzymes

2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulins, Biosimilar Growth Hormones, Biosimilar Erythropoietins, Biosimilar Granulocyte Colony-Stimulating Factors (G-CSFs)

Which Trends Are Expected To Shape The Biopharmaceutical CMO And CRO Market?

Leading companies operating within the biopharmaceutical third-party logistics market are concentrating on innovative solutions, such as expanding their business into life sciences and healthcare logistics, to strengthen their logistical capabilities for pharmaceutical and healthcare products, thereby ensuring efficient storage and distribution. This business expansion in life sciences and healthcare logistics signifies the strategic development of logistics firms to enhance their abilities in transporting and managing medical products, which is critical for guaranteeing timely delivery and preserving the integrity of temperature-sensitive items essential for patient care. For instance, in May 2025, DHL Group, a Germany-based logistics company, announced the grand opening of its upgraded Life Sciences & Healthcare (LSH) campus located in Florstadt, Germany. The new facility incorporates ultra-cold storage zones (down to –70°C), real-time visibility systems, and GDP-certified infrastructure, facilitating the secure handling of temperature-sensitive biopharmaceuticals, including mRNA vaccines, clinical trial materials, and advanced therapies.

Which Companies Form The Competitive Landscape Of The Biopharmaceutical CMO And CRO Market?

Major companies operating in the biopharmaceutical cmo and cro market are Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Eurofins Scientific SE, Lonza Group AG, Syneos Health Inc., Catalent Inc., Charles River Laboratories International Inc., Parexel International (MA) Corporation, Samsung Biologics Co. Ltd., CELLTRION INC., Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies UK Limited, Almac Group, Pharmaron Beijing Co. Ltd., Worldwide Clinical Trials, KBI Biopharma, Inotiv Inc., Caidya, Rentschler Biopharma SE, Celerion Inc., TFS HEALTHCARE LIMITED

Access The Complete Biopharmaceutical CMO And CRO Market Report:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-and-cro-global-market-report

What Is The Largest Regional Market In The Biopharmaceutical CMO And CRO Market?

North America was the largest region in the biopharmaceutical CMO and CRO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo and cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Biopharmaceutical CMO And CRO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=19337&type=smp

Browse Through More Reports Similar to the Global Biopharmaceutical CMO And CRO Market 2026, By The Business Research Company

Medical Biomimetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-biomimetics-global-market-report

Biosimilar Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Pharmaceuticals Market 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Coxsackievirus Infections Treatment Market Progress Between 2026 And 2030?

The coxsackievirus infections treatment market size has experienced strong expansion in recent years. It is projected to grow from $3.1 billion in 2025 to $3.35 billion in 2026, at a compound annual growth rate (CAGR) of 8.0%. The increase observed in the historic period can be ascribed to a high incidence of hand foot and mouth disease, the lack of specific antiviral therapy, the vulnerability of pediatric populations, hospital-centered treatment models, and seasonal infection patterns.

The coxsackievirus infections treatment market is anticipated to experience substantial expansion over the coming years. It will grow to $4.51 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. This expansion throughout the projected period stems from advancements in viral diagnostics, increased understanding of viral myocarditis dangers, broader availability of pediatric care, an emphasis on preventing complications, and ongoing research into antiviral treatments. Noteworthy developments during the forecast period encompass a heightened emphasis on managing supportive care, increased surveillance of pediatric infections, the broadening of hospital-based treatment guidelines, enhanced therapies for symptom alleviation, and the incorporation of preventive care approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/coxsackievirus-infections-treatment-global-market-report

Which Important Drivers Are Guiding The Coxsackievirus Infections Treatment Market Growth?

The widespread occurrence of viral infections causing hand, foot, and mouth disease (HFMD) is anticipated to drive the expansion of the coxsackievirus infections treatment market going forward. Hand, foot, and mouth disease (HFMD) is a common viral infection in children, characterized by fever, mouth sores, and a rash on the hands and feet, primarily caused by viruses such as coxsackievirus A16 and enterovirus 71. This is attributed to factors like close contact with infected individuals, poor hygiene, and exposure to respiratory droplets or contaminated surfaces. Coxsackievirus infection treatment helps manage symptoms of viral infections such as hand, foot, and mouth disease by providing supportive care, including pain relief, hydration, and fever management. For instance, in April 2024, the Indonesia Ministry of Health (MoH) reported that hand, foot, and mouth disease (HFMD) cases reached 6,500 in the first quarter of 2024, which was more than half of the 11,000 cases reported in 2023. Therefore, the significant prevalence of viral infection leading to hand, foot, and mouth disease (HFMD) is propelling the growth of the coxsackievirus infections treatment market.

How Is The Coxsackievirus Infections Treatment Market Organized By Segment Classification?

The coxsackievirus infections treatment market covered in this report is segmented –

1) By Treatment Type: Antiviral Medications, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Supportive Care

2) By Route Of Administration: Oral, Intravenous (IV), Topical, Inhalation

3) By Age Group: Pediatric Patients, Adult Patients, Geriatric Patients

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Outpatient Clinics, Home Care Settings, Educational Institutions (Daycare, Schools)

Subsegments:

1) By Antiviral Medications: Nucleoside Analogues, Protease Inhibitors, Polymerase Inhibitors

2) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Aspirin, Naproxen, Diclofenac

3) By Corticosteroids: Prednisone, Hydrocortisone, Methylprednisolone, Dexamethasone

4) By Supportive Care: Fluid Replacement Therapy, Pain Management, Fever Management, Rest and Nutrition

What Trends Are Influencing The Evolution Of The Coxsackievirus Infections Treatment Market?

Leading companies within the coxsackievirus infections treatment market are concentrating on clinical trials to develop advanced multivalent vaccines, aiming for wider protection and better disease prevention. These multivalent vaccines, designed to target several virus types at once, strengthen immune protection by tackling the issue of low cross-immunogenicity among various circulating enteroviruses. This approach boosts effectiveness, broadens coverage, and refines general disease control, particularly for conditions like HFMD, which stem from EV71, CA16, and associated coxsackieviruses. For instance, SINOVAC Biotech Ltd., a biopharmaceutical firm based in China, commenced a Phase III clinical trial in December 2024 for its investigational bivalent HFMD vaccine, engineered to offer protection against both Enterovirus 71 (EV71) and Coxsackievirus A16 (CA16). This specific Phase III trial, notable as the world’s first for a multivalent HFMD vaccine, builds upon positive outcomes regarding safety and immunogenicity observed in SINOVAC’s earlier Phase I/II study. Furthermore, the company has also created the globe’s first tetravalent enterovirus inactivated vaccine, designed to target EV71, CA16, CA10, and CA6. This vaccine has already secured clinical trial approval, further bolstering initiatives to broaden defense against coxsackievirus infections.

Who Are The Industry Participants Involved In The Coxsackievirus Infections Treatment Market?

Major companies operating in the coxsackievirus infections treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., CSL Behring, Grifols S.A., Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories, Octapharma AG, Rochem International Inc, AdvaCare Pharma, LGM Pharma.

Get The Full Coxsackievirus Infections Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/coxsackievirus-infections-treatment-global-market-report

Which Region Accounts For The Largest Portion Of The Coxsackievirus Infections Treatment Market?

North America was the largest region in the coxsackievirus infections treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coxsackievirus infections treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Coxsackievirus Infections Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/coxsackievirus-infections-treatment-global-market-report

Browse Through More Reports Similar to the Global Coxsackievirus Infections Treatment Market 2026, By The Business Research Company

Respiratory Syncytial Virus Rsv Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Oncolytic Virus Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Biopharmaceutical CMO And CRO Market Grow Between 2026 And 2030?

The biopharmaceutical cmo and cro market has demonstrated robust expansion recently. Its size is anticipated to increase from $35.6 billion in 2025 to $38.01 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.8%. This historical growth can be linked to several contributing factors, including the increasing complexity inherent in biologic drug development, the rising R&D expenditures for biopharmaceutical companies, the broader scope of clinical trial activities, the advancement in biosimilar development, and the presence of specialized contract service providers.

The biopharmaceutical cmo and cro market is projected to experience robust expansion over the coming years. This market is set to reach $48.79 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this anticipated growth include a heightened demand for sophisticated biologics production, increased capital allocation for cell and gene therapies, the broadening of worldwide clinical trial pipelines, an intensified emphasis on strategies for quicker market entry, and the greater uptake of digitalized CRO offerings. Key trends expected during this forecast timeframe encompass the expanding practice of outsourcing biologic drug production, an escalating need for comprehensive end-to-end contract research solutions, a developing preference for adaptable manufacturing capabilities, the broadening of support for cell and gene therapy development, and a reinforced focus on services ensuring regulatory adherence.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-and-cro-global-market-report

Which Drivers Are Supporting The Biopharmaceutical CMO And CRO Market Growth?

Increased allocation of funds towards research and development is projected to boost the expansion of the biopharmaceutical CMO and CRO market in the future. This increase in R&D funding stems from various reasons, including the push for novel solutions, intense competition, the necessity to meet changing market requirements, and governmental support. Such investments empower CMOs and CROs to develop improved manufacturing processes and research protocols, consequently enhancing their capacities and operational effectiveness. This focus on innovation attracts and retains customers by offering advanced solutions, all while ensuring adherence to regulatory standards. For instance, in September 2025, according to Eurostat, the Luxembourg-based statistical agency, the EU spent about $456 billion USD on research and development (R&D) in 2023 (€389 billion), and R&D expenditure relative to GDP rose to 2.26%, up from 2.22% in the previous year. Consequently, the increased spending on research and development is propelling the expansion of the biopharmaceutical CMO and CRO market.

How Is The Biopharmaceutical CMO And CRO Market Organized By Segment Classification?

The biopharmaceutical cmo and cro market covered in this report is segmented –

1) By Product: Biologics, Biosimilars

2) By Service Type: Contract Manufacturing, Contract Research

3) By Source: Mammalian, Non-Mammalian

Subsegments:

1) By Biologics: Monoclonal Antibodies (mAbs), Vaccines, Recombinant Proteins, Cell and Gene Therapies, Antibody-Drug Conjugates (ADCs), Therapeutic Enzymes

2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulins, Biosimilar Growth Hormones, Biosimilar Erythropoietins, Biosimilar Granulocyte Colony-Stimulating Factors (G-CSFs)

Which Trends Are Expected To Impact The Biopharmaceutical CMO And CRO Market?

Leading entities within the biopharmaceutical CMO and CRO market are establishing strategic collaborations with the goal of improving service offerings, boosting operational efficiencies, and speeding up drug development processes for biopharmaceutical organizations. These strategic partnerships represent a method where businesses utilize one another’s capabilities and assets to secure shared advantages and collective achievement. An illustrative example is seen in June 2024, when Abzena plc., a UK-based biopharmaceutical company, entered into a partnership with Argonaut Manufacturing Services Inc., a US-based contract manufacturing organization (CMO), for the purpose of combining drug development and manufacturing solutions tailored for clients. Through this collaboration, their objective is to deliver expedited, comprehensive drug development and manufacturing services designed to increase effectiveness, decrease expenditures, and simplify biopharmaceutical production for their clientele.

Who Are The Industry Participants Involved In The Biopharmaceutical CMO And CRO Market?

Major companies operating in the biopharmaceutical cmo and cro market are Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Eurofins Scientific SE, Lonza Group AG, Syneos Health Inc., Catalent Inc., Charles River Laboratories International Inc., Parexel International (MA) Corporation, Samsung Biologics Co. Ltd., CELLTRION INC., Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies UK Limited, Almac Group, Pharmaron Beijing Co. Ltd., Worldwide Clinical Trials, KBI Biopharma, Inotiv Inc., Caidya, Rentschler Biopharma SE, Celerion Inc., TFS HEALTHCARE LIMITED

Get The Full Biopharmaceutical CMO And CRO Market Report:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-and-cro-global-market-report

Which Region Holds The Highest Market Share In The Biopharmaceutical CMO And CRO Market?

North America was the largest region in the biopharmaceutical CMO and CRO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo and cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biopharmaceutical CMO And CRO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-and-cro-global-market-report

Browse Through More Reports Similar to the Global Biopharmaceutical CMO And CRO Market 2026, By The Business Research Company

Biopharmaceutical Third Party Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-third-party-logistics-global-market-report

Biopharmaceuticals Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Lyophilization Services For Biopharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/lyophilization-services-for-biopharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Biopharmaceutical CMO And CRO Market Grow Between 2026 And 2030?

The biopharmaceutical cmo and cro market has demonstrated robust expansion recently. Its size is anticipated to increase from $35.6 billion in 2025 to $38.01 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.8%. This historical growth can be linked to several contributing factors, including the increasing complexity inherent in biologic drug development, the rising R&D expenditures for biopharmaceutical companies, the broader scope of clinical trial activities, the advancement in biosimilar development, and the presence of specialized contract service providers.

The biopharmaceutical cmo and cro market is projected to experience robust expansion over the coming years. This market is set to reach $48.79 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this anticipated growth include a heightened demand for sophisticated biologics production, increased capital allocation for cell and gene therapies, the broadening of worldwide clinical trial pipelines, an intensified emphasis on strategies for quicker market entry, and the greater uptake of digitalized CRO offerings. Key trends expected during this forecast timeframe encompass the expanding practice of outsourcing biologic drug production, an escalating need for comprehensive end-to-end contract research solutions, a developing preference for adaptable manufacturing capabilities, the broadening of support for cell and gene therapy development, and a reinforced focus on services ensuring regulatory adherence.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-and-cro-global-market-report

Which Drivers Are Supporting The Biopharmaceutical CMO And CRO Market Growth?

Increased allocation of funds towards research and development is projected to boost the expansion of the biopharmaceutical CMO and CRO market in the future. This increase in R&D funding stems from various reasons, including the push for novel solutions, intense competition, the necessity to meet changing market requirements, and governmental support. Such investments empower CMOs and CROs to develop improved manufacturing processes and research protocols, consequently enhancing their capacities and operational effectiveness. This focus on innovation attracts and retains customers by offering advanced solutions, all while ensuring adherence to regulatory standards. For instance, in September 2025, according to Eurostat, the Luxembourg-based statistical agency, the EU spent about $456 billion USD on research and development (R&D) in 2023 (€389 billion), and R&D expenditure relative to GDP rose to 2.26%, up from 2.22% in the previous year. Consequently, the increased spending on research and development is propelling the expansion of the biopharmaceutical CMO and CRO market.

How Is The Biopharmaceutical CMO And CRO Market Organized By Segment Classification?

The biopharmaceutical cmo and cro market covered in this report is segmented –

1) By Product: Biologics, Biosimilars

2) By Service Type: Contract Manufacturing, Contract Research

3) By Source: Mammalian, Non-Mammalian

Subsegments:

1) By Biologics: Monoclonal Antibodies (mAbs), Vaccines, Recombinant Proteins, Cell and Gene Therapies, Antibody-Drug Conjugates (ADCs), Therapeutic Enzymes

2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulins, Biosimilar Growth Hormones, Biosimilar Erythropoietins, Biosimilar Granulocyte Colony-Stimulating Factors (G-CSFs)

Which Trends Are Expected To Impact The Biopharmaceutical CMO And CRO Market?

Leading entities within the biopharmaceutical CMO and CRO market are establishing strategic collaborations with the goal of improving service offerings, boosting operational efficiencies, and speeding up drug development processes for biopharmaceutical organizations. These strategic partnerships represent a method where businesses utilize one another’s capabilities and assets to secure shared advantages and collective achievement. An illustrative example is seen in June 2024, when Abzena plc., a UK-based biopharmaceutical company, entered into a partnership with Argonaut Manufacturing Services Inc., a US-based contract manufacturing organization (CMO), for the purpose of combining drug development and manufacturing solutions tailored for clients. Through this collaboration, their objective is to deliver expedited, comprehensive drug development and manufacturing services designed to increase effectiveness, decrease expenditures, and simplify biopharmaceutical production for their clientele.

Who Are The Industry Participants Involved In The Biopharmaceutical CMO And CRO Market?

Major companies operating in the biopharmaceutical cmo and cro market are Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Eurofins Scientific SE, Lonza Group AG, Syneos Health Inc., Catalent Inc., Charles River Laboratories International Inc., Parexel International (MA) Corporation, Samsung Biologics Co. Ltd., CELLTRION INC., Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies UK Limited, Almac Group, Pharmaron Beijing Co. Ltd., Worldwide Clinical Trials, KBI Biopharma, Inotiv Inc., Caidya, Rentschler Biopharma SE, Celerion Inc., TFS HEALTHCARE LIMITED

Get The Full Biopharmaceutical CMO And CRO Market Report:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-and-cro-global-market-report

Which Region Holds The Highest Market Share In The Biopharmaceutical CMO And CRO Market?

North America was the largest region in the biopharmaceutical CMO and CRO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo and cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biopharmaceutical CMO And CRO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-and-cro-global-market-report

Browse Through More Reports Similar to the Global Biopharmaceutical CMO And CRO Market 2026, By The Business Research Company

Biopharmaceutical Third Party Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-third-party-logistics-global-market-report

Biopharmaceuticals Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Lyophilization Services For Biopharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/lyophilization-services-for-biopharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Biopharmaceutical CMO And CRO Market From 2026 To 2030?

The biopharmaceutical contract manufacturing organization (CMO) and contract research organization (CRO) market has experienced robust expansion in recent times. This market is projected to expand from $35.6 billion in 2025 to $38.01 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this growth has been driven by factors such as the increasing intricacy of developing biologic drugs, escalating research and development (R&D) expenses for biopharmaceutical firms, the broadening of clinical trial operations, the surge in biosimilar product development, and the presence of dedicated contract service providers.

The biopharmaceutical cmo and cro market is projected to experience substantial expansion in the coming years. By 2030, its size is anticipated to reach $48.79 billion, demonstrating a compound annual growth rate (CAGR) of 6.4%. This projected growth is driven by several factors, including a heightened demand for advanced biologics production, increased investments in cell and gene therapies, the expansion of global clinical trial pipelines, a greater emphasis on strategies for faster market entry, and the increasing uptake of digitalized CRO services. Key trends for the forecast period encompass a rise in the outsourcing of biologic drug manufacturing, a growing need for comprehensive end-to-end contract research services, an increased focus on adaptable manufacturing capabilities, expanded support for cell and gene therapy development, and a stronger emphasis on regulatory compliance assistance.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19337&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Biopharmaceutical CMO And CRO Market?

Increased spending on research and development is projected to boost the expansion of the biopharmaceutical CMO and CRO market in the coming period. Such investments in R&D are escalating due to several reasons, including the demand for innovation, competitive pressures, the necessity to address evolving market requirements, and government incentives. Research and development funding empowers CMOs and CROs to develop advanced manufacturing methods and research protocols, thereby enhancing their capabilities and operational effectiveness. This commitment to innovation attracts and retains clients by delivering cutting-edge solutions while consistently ensuring regulatory compliance. For instance, Eurostat, the Luxembourg-based statistical agency, indicated in September 2025 that the EU spent approximately $456 billion USD on research and development (R&D) in 2023 (€389 billion), with R&D expenditure relative to GDP rising to 2.26%, up from 2.22% in the preceding year. Hence, the growing investment in research and development is fueling the growth of the biopharmaceutical CMO and CRO market.

Which Segments Are Included In The Analysis Of The Biopharmaceutical CMO And CRO Market?

The biopharmaceutical cmo and cro market covered in this report is segmented –

1) By Product: Biologics, Biosimilars

2) By Service Type: Contract Manufacturing, Contract Research

3) By Source: Mammalian, Non-Mammalian

Subsegments:

1) By Biologics: Monoclonal Antibodies (mAbs), Vaccines, Recombinant Proteins, Cell and Gene Therapies, Antibody-Drug Conjugates (ADCs), Therapeutic Enzymes

2) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulins, Biosimilar Growth Hormones, Biosimilar Erythropoietins, Biosimilar Granulocyte Colony-Stimulating Factors (G-CSFs)

What Trends Are Affecting The Expansion Of The Biopharmaceutical CMO And CRO Market?

Leading companies within the biopharmaceutical CMO and CRO market are forming strategic alliances to bolster services, improve operational efficiencies, and accelerate the drug development process for biopharmaceutical firms. Strategic partnerships involve companies utilizing each other’s strengths and resources to achieve mutual benefits and success. As an illustration, in June 2024, Abzena plc., a UK-based biopharmaceutical company, collaborated with Argonaut Manufacturing Services Inc., a US-based contract manufacturing organization (CMO), to integrate drug development and manufacturing solutions for clients. Through this partnership, they aim to provide accelerated, end-to-end drug development and manufacturing solutions that enhance efficiency, reduce costs, and streamline biopharmaceutical production for clients.

Which Key Industry Participants Are Active In The Biopharmaceutical CMO And CRO Market?

Major companies operating in the biopharmaceutical cmo and cro market are Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Eurofins Scientific SE, Lonza Group AG, Syneos Health Inc., Catalent Inc., Charles River Laboratories International Inc., Parexel International (MA) Corporation, Samsung Biologics Co. Ltd., CELLTRION INC., Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies UK Limited, Almac Group, Pharmaron Beijing Co. Ltd., Worldwide Clinical Trials, KBI Biopharma, Inotiv Inc., Caidya, Rentschler Biopharma SE, Celerion Inc., TFS HEALTHCARE LIMITED

Read the full biopharmaceutical cmo and cro market report here:

https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-and-cro-global-market-report

What Are The Leading Geographic Regions In The Biopharmaceutical CMO And CRO Market?

North America was the largest region in the biopharmaceutical CMO and CRO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo and cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biopharmaceutical CMO And CRO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19337&type=smp

Browse Through More Reports Similar to the Global Biopharmaceutical CMO And CRO Market 2026, By The Business Research Company

Medical Biomimetics Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-biomimetics-global-market-report

Biosimilar Global Market Report

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Pharmaceuticals Market

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model